MA55280A - Formulation solide de modulateur d'assemblage de capside - Google Patents

Formulation solide de modulateur d'assemblage de capside

Info

Publication number
MA55280A
MA55280A MA055280A MA55280A MA55280A MA 55280 A MA55280 A MA 55280A MA 055280 A MA055280 A MA 055280A MA 55280 A MA55280 A MA 55280A MA 55280 A MA55280 A MA 55280A
Authority
MA
Morocco
Prior art keywords
solid formulation
assembly modulator
capside
capside assembly
modulator
Prior art date
Application number
MA055280A
Other languages
English (en)
French (fr)
Inventor
Michaël Bertil S Anné
Claire Elisabeth Balmain
Maria Jansens
Oliver Lenz
Abhishek Singh
Jan Snoeys
Dycke Frederic Anne R Van
Joris Jozef Vandenbossche
Dominique Josiane W Verstraete
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/352,754 external-priority patent/US10973801B2/en
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of MA55280A publication Critical patent/MA55280A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA055280A 2019-03-13 2020-03-13 Formulation solide de modulateur d'assemblage de capside MA55280A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16/352,754 US10973801B2 (en) 2018-03-14 2019-03-13 Capsid assembly modulator dosing regimen
PCT/IB2019/000231 WO2019175657A1 (en) 2018-03-14 2019-03-13 Capsid assembly modulator dosing regimen
EP2019056348 2019-03-13
EP19197566 2019-09-16

Publications (1)

Publication Number Publication Date
MA55280A true MA55280A (fr) 2022-01-19

Family

ID=72427202

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055280A MA55280A (fr) 2019-03-13 2020-03-13 Formulation solide de modulateur d'assemblage de capside

Country Status (16)

Country Link
EP (1) EP3937928A1 (es)
JP (1) JP2022524819A (es)
KR (1) KR20210137484A (es)
CN (1) CN113557016A (es)
AU (1) AU2020235442A1 (es)
BR (1) BR112021017525A2 (es)
CA (1) CA3132095A1 (es)
CR (1) CR20210481A (es)
EC (1) ECSP21067052A (es)
IL (1) IL286209A (es)
JO (1) JOP20210250A1 (es)
MA (1) MA55280A (es)
MX (1) MX2021011030A (es)
PE (1) PE20212107A1 (es)
SG (1) SG11202109710QA (es)
WO (1) WO2020183020A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019511542A (ja) 2016-04-15 2019-04-25 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー カプシド集合阻害剤を含む組み合わせ及び方法
AU2019235522A1 (en) * 2018-03-14 2020-09-03 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
AU2019235522A1 (en) * 2018-03-14 2020-09-03 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen

Also Published As

Publication number Publication date
PE20212107A1 (es) 2021-11-04
EP3937928A1 (en) 2022-01-19
BR112021017525A2 (pt) 2021-11-23
JOP20210250A1 (ar) 2023-01-30
KR20210137484A (ko) 2021-11-17
IL286209A (en) 2021-10-31
CA3132095A1 (en) 2020-09-17
CN113557016A (zh) 2021-10-26
CR20210481A (es) 2021-10-25
ECSP21067052A (es) 2021-11-18
WO2020183020A1 (en) 2020-09-17
AU2020235442A1 (en) 2021-08-12
SG11202109710QA (en) 2021-10-28
MX2021011030A (es) 2021-10-13
JP2022524819A (ja) 2022-05-10

Similar Documents

Publication Publication Date Title
EP3897522A4 (en) MICROCAPSULE COMPOSITION
EP3877521A4 (en) LIPID NANOPARTICLE FORMULATIONS
IL287660A (en) Transmuted cycloalkyls as modulators of combined stress pathways
MA52019A (fr) Schéma posologique de modulateur d'assemblage de capside
EP3784707A4 (en) STABLE POLYURA MICROCAPSULE COMPOSITIONS
MA51903A (fr) Formulations d'anticorps b7-h4
MA54521A (fr) Dérivés d'oxopyridine substitués
EP3773721A4 (en) STABLE ANTI-CD79B IMMUNOCONJUGATE FORMULATIONS
EP3749309A4 (en) HYPERTONIC PHARMACEUTICAL COMPOSITIONS CONTAINING AN ANTI-PLATINUM CHEMOPROTECTIVE AGENT
CL2021002141A1 (es) Anticuerpos claudina 6 y usos de los mismos.
MA54052A (fr) Formulation d'anticorps
EP3828287A4 (en) MCI DIAGNOSTIC MARKERS DUE TO AD AND APPLICATION THEREOF
MA53924A (fr) Modulateurs de l'expression d'apol1
MA55280A (fr) Formulation solide de modulateur d'assemblage de capside
MA54139A (fr) Formulation d'anticorps
EP3977855A4 (en) STABLE MICROBICIDE COMPOSITION
MA50570A (fr) Formulations de fulvestrant et méthodes d'utilisation de ces dernières
IL283450A (en) capsule formulations
MA50547A (fr) Composés et compositions d'induction de la chondrogenèse
EP4007590A4 (en) FORMULATIONS INCLUDING DIHYDROHONOKIOL
EP3829532A4 (en) KERATINA COMPOSITIONS
MA52188A (fr) Formulation solide de mélanges fongicides
MA51645A (fr) Modulateurs de l'expression de dnm2
ES2974424T3 (es) Formulaciones
MA52874A (fr) Formulations/compositions comprenant de l'ibrutinib